Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002022805 - MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES

Publication Number WO/2002/022805
Publication Date 21.03.2002
International Application No. PCT/US2001/028612
International Filing Date 14.09.2001
Chapter 2 Demand Filed 10.04.2002
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
C07K 14/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
C07K 14/55 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
55IL-2
CPC
A61K 38/2013
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2013IL-2
A61K 38/2086
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2086IL-13 to IL-16
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61P 17/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
Applicants
  • BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US]/[US] (AllExceptUS)
  • LI, Xian, Chang [--]/[US] (UsOnly)
  • STROM, Terry [US]/[US] (UsOnly)
  • ZHENG, Xin, Xiao [CN]/[US] (UsOnly)
Inventors
  • LI, Xian, Chang
  • STROM, Terry
  • ZHENG, Xin, Xiao
Agents
  • FREEMAN, John, W.
Priority Data
60/232,25114.09.2000US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES
(FR) MODULATION DE REACTIONS DE CELLULES T INDUITES PAR IL-15 ET IL-2
Abstract
(EN)
The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo, reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).
(FR)
L'invention concerne en partie les études d'expression des sous-unités de récepteur IL-15 et IL-2 par le cycle de cellules T in vivo. Selon un mode de réalisation, l'invention présente de nouvelles combinaisons d'antagonistes de IL-15 et IL-2 et des procédés de suppression de la réaction immunitaire par l'administration de ces antagonistes. Dans chaque cas, on réalise la suppression en administrant un premier agent qui cible une molécule IL-15 ou un récepteur IL-15 (IL-15R) et un second agent qui cible une molécule IL-2 ou un récepteur IL IL-2 (IL-2R). En général, l'invention concerne de nouvelles combinaisons d'agents qui, lorsqu'ils sont administrés à un patient (ou un transplant ex vivo, réduisent le nombre de cellules T réagissant à l'antigène. L'invention décrit, par exemple, des compositions (e.g., compositions pharmaceutiquement acceptables) comportant deux ou plus d'agents, chacun d'eux favorisant la destruction des cellules T. Par ailleurs, la composition peut également contenir au moins un agent qui favorise la destruction des cellules T et au moins un agent qui inhibe la prolifération des cellules T. L'agent favorisant la destruction des cellules T peut aussi aider à l'AICD (destruction des cellules induite par activation), la destruction de cellules passive, l'ADCC (la cytotoxicité induite par des cellules dépendant d'un anticorps) ou la CDC (cytotoxicité dirigée vers un complément).
Latest bibliographic data on file with the International Bureau